The saxagliptin market was valued at USD 1.73 Billion in 2025 and is expected to grow at a CAGR of 7.20%, reaching USD 3.47 Billion by 2035. Growth is fueled by rising prevalence of type 2 diabetes and increased adoption of DPP-4 inhibitors.
Base Year
Historical Period
Forecast Period
The market is expected to grow steadily, driven by increasing diabetes prevalence and the rising demand for effective and convenient oral antidiabetic medications.
Regulatory advancements and the introduction of generic alternatives are anticipated to enhance market accessibility, making Saxagliptin more affordable across emerging and developed regions.
Collaborative research and development efforts between pharmaceutical companies and healthcare providers are likely to foster innovations in combination therapies, further expanding the potential of Saxagliptin in diabetes management.
Compound Annual Growth Rate
7.2%
Value in USD Billion
2026-2035
*this image is indicative*
Saxagliptin is a medication used to help control blood sugar levels in people with type 2 diabetes. It works by increasing the amount of insulin your body makes after eating, which helps lower blood sugar levels. Saxagliptin belongs to a group of drugs called DPP-4 inhibitors and is usually taken as a pill once a day. It can be used alone or with other diabetes medications, like metformin. Along with a balanced diet and exercise, Saxagliptin can help manage diabetes and reduce the risk of complications.
Rising Global Diabetes Prevalence Driving Market Growth
The International Diabetes Federation estimates that approximately 537 million adults live with diabetes, with type 2 diabetes accounting for 95% of cases. This number is expected to rise to 643 million by 2030, and 783 million by 2045. This rapid growth in diabetes prevalence, coupled with the fact that many people remain undiagnosed, underscores the need for more effective treatments. The high burden in low- and middle-income countries, where a large proportion of diabetic patients reside, is expected to fuel the demand for affordable treatment options. The increasing patient population will drive significant market expansion, particularly for affordable generics, ensuring that market growth will continue over the forecast period.
Availability of Generic Versions to Meet Rising Saxagliptin Market Demand
In August 2023, Dr. Reddy’s Laboratories launched its generic version of KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended-release tablets) in the United States market. Approved by the U.S. Food and Drug Administration, this launch includes various strengths, such as 2.5 mg/1000 mg, 5 mg/500 mg, and 5 mg/1000 mg. This move strengthens Dr. Reddy’s position in the diabetes treatment market by providing an affordable alternative to the branded formulation. The launch is expected to enhance competition, offering more accessible treatment options, especially in price-sensitive markets. This expansion will likely lead to further growth in the global saxagliptin market, contributing to increased market value and competition during the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Saxagliptin Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Market Breakup by Dosage Type
Market Breakup by Application
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
5mg Dosage Form to Lead the Segmentation by Dosage Type
The 5mg dosage of saxagliptin is poised to hold the largest market share by dosage type, driven by its optimal therapeutic effectiveness and widespread usage in diabetes management. This dosage is preferred due to its balanced risk-to-benefit profile, ensuring enhanced patient compliance. The demand for the 5mg dose is expected to rise as more patients are diagnosed with type 2 diabetes globally, especially in emerging markets. As treatment regimens for diabetes become more standardised, this dosage will continue to dominate due to its proven efficacy in managing blood glucose levels, driving significant market growth in the forecast period.
Type 2 Diabetes to Dominate the Saxagliptin Market Segmentation by Application
Type 2 diabetes is expected to hold the largest market share in the saxagliptin segment due to the high and increasing prevalence of the condition worldwide. Saxagliptin’s effectiveness in managing blood sugar levels makes it the first choice for patients with type 2 diabetes, especially as lifestyle factors contribute to the rising incidence. As per the analysis by Expert Market Research, the type 2 diabetes market is expected to grow at a CAGR of 8.4% during the forecast period of 2025-2034. Additionally, the growing awareness of diabetes management and the development of more accessible treatment options is expected to boost demand. As the focus on chronic disease management intensifies, the type 2 diabetes application will continue to drive substantial market growth through the forecast period.
Online Pharmacies to Hold a Substantial Saxagliptin Market Value for Segmentation by Distribution Channel
Online pharmacies are projected to lead the market by distribution channel due to the growing trend of e-commerce and patient convenience. The increasing preference for online shopping, coupled with the COVID-19 pandemic’s impact, has accelerated the adoption of online pharmacies. The availability of saxagliptin through online platforms allows patients to access medications easily and at competitive prices. This segment is poised for rapid growth, supported by advancements in digital healthcare, a rise in the use of telemedicine, and greater patient trust in e-pharmacies, all contributing to market expansion in the coming years.
North America is likely to hold the largest market share for saxagliptin due to the advanced healthcare infrastructure, high diabetes prevalence, and strong consumer demand for effective treatments. The region has a well-established pharmaceutical market with robust reimbursement policies, facilitating easier access to treatments. Furthermore, the increasing adoption of personalised diabetes management will further drive growth. While Europe shows steady growth driven by increasing healthcare investments, Asia Pacific is expanding rapidly due to rising diabetes cases and improving healthcare access.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Cambridge, UK, AstraZeneca was established in 1999 through the merger of Astra AB and Zeneca Group. The company is a global leader in biopharmaceuticals, focusing on oncology, cardiovascular, renal, and metabolic diseases. In June 2024, AstraZeneca's Farxiga (Dapagliflozin) received FDA approval to improve glycemic control in children aged 10 years and older with type 2 diabetes, underscoring its ongoing commitment to advancing diabetes care. AstraZeneca's diverse portfolio and continuous innovation cement its position at the forefront of the diabetes management market, including treatments for both adults and paediatric patients with type 2 diabetes.
Aurobindo Pharma, founded in 1986 and headquartered in Hyderabad, India, is a major player in the global generic pharmaceuticals market. It has a robust portfolio, including treatments for cardiovascular, central nervous system, and anti-infective therapies. In July 2023, Aurobindo received final approval from the U.S. FDA for its Abbreviated New Drug Application for saxagliptin tablets, a generic version of AstraZeneca’s Onglyza. This approval positions Aurobindo as a significant player in providing affordable treatment options for type 2 diabetes, contributing to expanding global access to essential diabetes medications at competitive prices.
Dr. Reddy’s Laboratories, established in 1984 and headquartered in Hyderabad, India, is a leading global pharmaceutical company. It offers a wide range of generic medicines, active pharmaceutical ingredients (APIs), and biosimilars, with a strong presence in the U.S., Europe, and emerging markets. Dr. Reddy’s has a significant role in diabetes care with products like generic versions of popular medications. The company's ongoing investments in R&D help maintain its leadership in global healthcare, providing affordable and accessible treatments for chronic conditions, including diabetes.
Founded in 1977 and headquartered in Mumbai, India, Glenmark Pharmaceuticals is a global pharmaceutical company with a comprehensive portfolio across key therapeutic areas such as oncology, dermatology, and respiratory diseases. In February 2023, Glenmark Pharmaceuticals USA received a second tentative approval from the U.S. FDA for Saxagliptin Tablets, 2.5 mg and 5 mg, a generic version of Onglyza. This approval significantly broadens access to diabetes treatments, reinforcing Glenmark’s commitment to improving healthcare outcomes globally. The company continues to expand its offerings, contributing to enhanced accessibility of diabetes care worldwide.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Kavya Pharma, Lupin, and Wellona Pharma.
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Dosage Type |
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share